73 related articles for article (PubMed ID: 2117483)
1. Immunotherapeutic approaches to leukemia: the use of the Friend virus-induced erythroleukemia model system.
Johnson CS; Chang MJ; Thurlow SM; Pourbohloul SC; Furmanski P
Cancer Res; 1990 Sep; 50(17 Suppl):5682S-5686S. PubMed ID: 2117483
[TBL] [Abstract][Full Text] [Related]
2. Induction of leukemia regression in mice by immunotherapeutic transfer of T-lymphocytes.
Johnson CS; Thurlow SM; Furmanski P
Cancer Res; 1986 Jan; 46(1):183-9. PubMed ID: 3079585
[TBL] [Abstract][Full Text] [Related]
3. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice.
Yoshimura A; Shiku H; Nakayama E
J Immunol; 1993 Jun; 150(11):4900-10. PubMed ID: 8496592
[TBL] [Abstract][Full Text] [Related]
4. Lymphokine-activated killer cell plus recombinant interleukin-2 therapy of erythroleukemia in mice.
Johnson CS; Thurlow SM; Furmanski P
Leukemia; 1989 Feb; 3(2):91-6. PubMed ID: 2783472
[TBL] [Abstract][Full Text] [Related]
5. Erythroid leukemia induced by Friend lymphatic leukemia virus in T-cell-depleted mice.
Dawson PJ; Dresler SL; Fieldsteel AH
Cancer Res; 1979 May; 39(5):1611-5. PubMed ID: 311686
[TBL] [Abstract][Full Text] [Related]
6. Spontaneous regression of Friend murine leukemia virus-induced erythroleukemia. IV. Effects of radiation and athymia on leukemia regression in mice.
Furmanski P; Dietz M; Fouchey S; Hall L; Clymer R; Rich MA
J Natl Cancer Inst; 1979 Aug; 63(2):449-54. PubMed ID: 287833
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of macrophage reversal of Friend erythroleukemia: macrophage regulation of normal and leukemic erythropoiesis.
Johnson CS; Thurlow SM; Marcelletti JF; Furmanski P
Cancer Res; 1986 Aug; 46(8):3896-902. PubMed ID: 3460693
[TBL] [Abstract][Full Text] [Related]
8. Loss of p53 tumor suppressor function is required for in vivo progression of Friend erythroleukemia.
Prasher JM; Elenitoba-Johnson KS; Kelley LL
Oncogene; 2001 May; 20(23):2946-55. PubMed ID: 11420707
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of mouse alpha/beta-interferon of the multiplication of alpha/beta-interferon-resistant Friend erythroleukemia cells cocultured with mouse hepatocytes.
Yasui H; Proietti E; Vignaux F; Eid P; Gresser I
Cancer Res; 1990 Jun; 50(12):3533-9. PubMed ID: 2140290
[TBL] [Abstract][Full Text] [Related]
10. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
11. Spontaneous regression of Friend virus-induced erythroleukemia. III. The role of macrophages in regression.
Marcelletti J; Furmanski P
J Immunol; 1978 Jan; 120(1):1-8. PubMed ID: 203629
[TBL] [Abstract][Full Text] [Related]
12. Spontaneous regression of Friend murine leukemia virus-induced erythroleukemia. V. Cell-mediated antivirus immunity in mice undergoing erythroleukemia regression and in leukemic mice.
Johnson CS; Fouchey SP; Furmanski P
J Natl Cancer Inst; 1980 Mar; 64(3):645-53. PubMed ID: 6965511
[No Abstract] [Full Text] [Related]
13. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor.
Chong AS; Scuderi P; Grimes WJ; Hersh EM
J Immunol; 1989 Mar; 142(6):2133-9. PubMed ID: 2493506
[TBL] [Abstract][Full Text] [Related]
14. Il-4 is an endogenous T cell growth factor during the immune response to a syngeneic retrovirus-induced tumor.
Kern DE; Peace DJ; Klarnet JP; Cheever MA; Greenberg PD
J Immunol; 1988 Oct; 141(8):2824-30. PubMed ID: 2459230
[TBL] [Abstract][Full Text] [Related]
15. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.
Thompson JA; Peace DJ; Klarnet JP; Kern DE; Greenberg PD; Cheever MA
J Immunol; 1986 Dec; 137(11):3675-80. PubMed ID: 3491145
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody against IFN-gamma inhibits Moloney murine sarcoma virus-specific cytotoxic T lymphocyte differentiation.
Zanovello P; Vallerani E; Biasi G; Landolfo S; Collavo D
J Immunol; 1988 Feb; 140(4):1341-4. PubMed ID: 2830339
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the early and late stages of myelomonocytic leukemia induced by Friend helper-independent virus F-MuLV: isolation and induction of Friend myelomonocytic leukemic cell lines.
Shibuya T; Mak TW
J Cell Physiol; 1983 Dec; 117(3):283-9. PubMed ID: 6581171
[TBL] [Abstract][Full Text] [Related]
18. Clonal heterogeneity of anti-AKR/gross leukemia virus cytotoxic T lymphocytes. Evidence for two distinct antigen systems.
Azuma H; Phillips JD; Green WR
J Immunol; 1987 Oct; 139(7):2464-73. PubMed ID: 2821116
[TBL] [Abstract][Full Text] [Related]
19. Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia.
Greenberg PD
J Immunol; 1986 Mar; 136(5):1917-22. PubMed ID: 3485134
[TBL] [Abstract][Full Text] [Related]
20. Purification and further characterization of a non-tumor necrosis factor alpha or beta differentiation-inducing cytokine, P48.
Leftwich JA; Hall RE
Cancer Res; 1989 Aug; 49(16):4459-65. PubMed ID: 2663142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
